Paricalcitol and Rashes - a phase IV clinical study of FDA data

Summary:

Rashes is reported as a side effect among people who take Paricalcitol (paricalcitol), especially for people who are male, 40-49 old, also take Renagel, and have Hypothyroidism.

The phase IV clinical study analyzes which people have Rashes when taking Paricalcitol. It is created by eHealthMe based on reports of 1,275 people who have side effects when taking Paricalcitol from the FDA, and is updated regularly.

What is Paricalcitol?

Paricalcitol has active ingredients of paricalcitol. eHealthMe is studying from 1,278 Paricalcitol users. Check the latest studies of Paricalcitol.

What is Rashes?

Rashes (redness) is found to be associated with 3,712 drugs and 6,213 conditions by eHealthMe. Check the latest studies of Rashes.

On Jul, 19, 2026

1,275 people reported to have side effects when taking Paricalcitol.
Among them, 32 people (2.51%) have Rashes.

Among these 32 people:

What is the gender of people who have Rashes when taking Paricalcitol? *

female: 50 %
male: 50 %

What is the age of people who have Rashes when taking Paricalcitol? *

What are other drugs people take besides Paricalcitol? *

What are other side effects people have besides Rashes? *

Oedema Peripheral (superficial swelling): 10 people, 31.25%
Nephrogenic Systemic Fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease): 10 people, 31.25%
Pain Of Skin: 10 people, 31.25%
Pain In Extremity: 10 people, 31.25%
Skin Hyperpigmentation (disorders affect the colour of your skin): 10 people, 31.25%
Skin Induration (an abnormally hard spot or area on the skin): 10 people, 31.25%
Skin Exfoliation (removal of the oldest dead skin cells): 9 people, 28.12%
Skin Fibrosis (fibrous tissue formation on skin): 9 people, 28.12%
Itching: 7 people, 21.88%
Skin Necrosis (skin damage): 6 people, 18.75%

What are the existing conditions these people have? *

Type 2 Diabetes: 5 people, 15.62%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 5 people, 15.62%
Nuclear Magnetic Resonance Imaging Brain: 4 people, 12.50%
Pain: 3 people, 9.38%
Nephrogenic Anaemia (anaemia due to kidney disease): 3 people, 9.38%
Hyperparathyroidism (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium): 3 people, 9.38%
Hyperparathyroidism Secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary): 3 people, 9.38%
Prostate Cancer: 2 people, 6.25%
Urinary Tract Infection: 1 person, 3.12%
Hyperparathyroidism Tertiary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-tertiary): 1 person, 3.12%

* Approximation only. Some reports may have incomplete information.

Do you take Paricalcitol and have Rashes?

- Check whether Rashes is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Paricalcitol:

Paricalcitol (1,278 reports)

Rashes treatments and more:

Rashes (702,909 reports)

Browse all side effects of Paricalcitol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Rashes:

Rashes (3,712 drugs)

Browse all the conditions that are associated with Rashes:

Rashes (6,213 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on paricalcitol (the active ingredients of Paricalcitol) and Paricalcitol (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.